Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 5/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3665238 | 1.00 | HCRTR1 (0.44) | HCRTR1HCRTR2PROKR1GLAHSD17B10 | |
| SCHEMBL3182822 | 1.00 | HCRTR1 (0.44) | HCRTR1HCRTR2PROKR1GLAHSD17B10 | |
| SCHEMBL3181421 | 0.91 | HCRTR2 (0.46) | HCRTR1HCRTR2PROKR1LMNAHSD11B1 | |
| SCHEMBL3181045 | 0.91 | HCRTR2 (0.46) | HCRTR1HCRTR2PROKR1LMNAHSD11B1 | |
| SCHEMBL3175324 | 0.91 | HCRTR2 (0.46) | HCRTR1HCRTR2PROKR1LMNAHSD11B1 | |
| SCHEMBL3662497 | 0.90 | HCRTR1 (0.44) | HCRTR1HCRTR2LMNAHSD11B1GRM5 | |
| SCHEMBL3165998 | 0.90 | HCRTR1 (0.44) | HCRTR1HCRTR2LMNAHSD11B1GRM5 | |
| SCHEMBL3173489 | 0.90 | HCRTR1 (0.44) | HCRTR1HCRTR2LMNAHSD11B1GRM5 | |
| SCHEMBL3658411 | 0.88 | HCRTR1 (0.45) | HCRTR1HCRTR2HSD11B1GRM5NPC1 | |
| SCHEMBL3185587 | 0.88 | HCRTR1 (0.45) | HCRTR1HCRTR2HSD11B1GRM5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231650-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Biovitrum AB (publ) (SE) | 2010-09-29 | — | — | EP | claimed |
| US-20100022590-A1 | Novel compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-01-28 | — | — | US | claimed |
| WO-2009090239-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (PUBL) (SE) | 2009-07-23 | — | — | WO | claimed |
| EP-2231650-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Biovitrum AB (publ) (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20100022590-A1 | Novel compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022590-A1 | Novel compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022590-A1 | Novel compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-01-28 | — | — | US | disclosed |
| WO-2009090239-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (PUBL) (SE) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009090239-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (PUBL) (SE) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022590-A1 | Novel compounds | HSD11B1, CYP11B1, HSD11B2 | HCRTR1 1030/4885HCRTR2 1087/4885PROKR1 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.